D
uchenne muscular dystrophy (DMD) is a fatal muscle disease affecting 1 in 3500 to 5000 boys. Cardiomyopathy and heart failure are common, incurable, and lethal consequences of DMD. The disease is caused by mutations in the gene encoding dystrophin, a large intracellular protein that links the dystroglycan complex at the cell surface with the underlying cytoskeleton, thereby maintaining integrity of muscle cell membranes during contraction (1, 2) . In the absence of dystrophin, muscles degenerate, causing weakness and myopathy (3) . Many therapeutic approaches for DMD have failed, at least in part because of the size of the dystrophin protein and the necessity for lifelong restoration of dystrophin expression in the myriad skeletal muscles of the body as well as the heart.
The CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) system allows precise modification of the genome and represents a potential means of correcting disease-causing mutations (4, 5) . In the presence of single guide RNAs (sgRNAs), Cas9 is directed to specific sites in the genome adjacent to a protospacer adjacent motif (PAM), causing a double-strand break (DSB). When provided with an additional DNA template, a precise genomic modification is generated by homology-directed repair (HDR), whereas in the absence of an exogenous template, variable indel mutations are created at the target site via nonhomologous end joining (NHEJ) (6) . Previously, we used CRISPR/ Cas9 to correct a single nonsense mutation in Dmd by HDR in the germ line of mdx mice, which allowed the restoration of dystrophin protein expression (7). However, germline genomic editing is not feasible in humans (8) and HDR does not occur in postmitotic adult tissues, such as heart and skeletal muscle (9) , necessitating alternative strategies of gene correction in postnatal tissues. Here, we devised a method to correct Dmd mutations by CRISPR/Cas9-mediated NHEJ (termed "Myoediting") in postnatal muscle tissues after delivery of gene-editing components by means of adeno-associated virus-9 (AAV9), which displays high tropism for muscle (10, 11) .
The dystrophin protein contains several domains ( fig. S1 ), including an actin-binding domain at the N terminus, a central rod domain with a series of spectrin-like and actin-binding repeats, and WW and cysteine-rich domains at the C terminus that mediate binding to dystroglycan, dystrobrevin, and syntrophin (12) . The actinbinding and cysteine-rich domains are essential for function, but many regions of the protein are dispensable (3) . It has been estimated that as many as 80% of DMD patients could benefit from exon-skipping strategies that bypass mutations in nonessential regions of the gene and partially restore dystrophin expression (13) . This approach has been validated in vitro by CRISPR/Cas9-mediated correction of Dmd mutations in patients' induced pluripotent stem cells (14) and immortalized myoblasts (15) . Similarly, adenovirus-mediated gene editing was shown to restore dystrophin expression in specific muscles of mdx mice after intramuscular injection (16), but adenoviral delivery is not therapeutically favorable (17) .
Shown in Fig. 1A is the strategy whereby CRISPR/Cas9-mediated NHEJ can create internal genomic deletions to bypass the premature termination codon in exon 23 responsible for the dystrophic phenotype of mdx mice, potentially allowing reconstitution of the Dmd open reading frame. In principle, this approach could be applied to many mutations within the gene, including large deletions, duplications, and pseudoexons. An advantage of this approach is that it does not require precise correction of the disease-causing mutation. Instead, imprecise deletions that prevent splicing of mutant exons are sufficient to restore dystrophin protein expression.
To test whether Myoediting could be adapted to skip the Dmd mutation in exon 23 in mdx mice, we first evaluated a pool of sgRNAs that potentially target the 5′ and 3′ ends of exon 23 (supplementary materials, fig. S2 , and table S1). We co-injected Cas9 mRNA with sgRNA-mdx (directed toward the mutant sequence in exon 23) and either sgRNA-R3 or sgRNA-L8 (targeting the 3′ and 5′ end of exon 23, respectively) into mdx zygotes without a HDR template ( fig. S3A ). Strikingly, 80% of progeny mice lacked exon 23 (termed mdx-DEx23) ( fig. S3 , B and C, and table S2), representing an increase in the efficiency of mdx editing relative to HDR (7) . S4A ). In mdx-DEx23 mice, serum creatine kinase levels (a measure of muscle membrane permeability) and grip-strength tests both showed restoration of muscle function ( fig. S4 , B and C). Control mdx mice without treatment (-) and mdx mice with Myoediting (+) were tested for potential off-target effects of Myoediting with sgRNA-R3 ( fig. S5 ). Ten potential genome-wide off-target sites (OT-01 to OT-10) were predicted by the CRISPR design tool (http://crispr.mit.edu; see supplementary materials and table S4) (7) . Only the target site Dmd R3 of Myoedited mdx mice showed cleavage bands in the T7 endonuclease I (T7E1) assay, and no off-target effects were detected in the top 10 potential off-target sites ( fig. S5 ).
To apply Myoediting to postnatal muscle tissues, we used AAV9, which displays tropism to cardiac and skeletal muscle (10, 11) , to deliver Cas9 and sgRNAs to muscles of mice. AAV-guide RNAs were generated by cloning sgRNA-mdx and sgRNA-R3 into AAV-sgRNA vector containing a human U6 promoter and green fluorescent protein (GFP) (Fig. 1B) . We generated AAV-Cas9 using a unique AAV-Cas9 vector (miniCMV-Cas9-shortPolyA) (18, 19) , which uses a "mini"-CMV promoter/ enhancer sequence to drive expression of the humanized Streptococcus pyogenes Cas9 (SpCas9). Different modes of AAV9 delivery and variations in timing of expression were systematically compared to identify the optimal method for Dmd Myoediting in postnatal mdx mice: (i) intramuscular (IM) at P12, (ii) retro-orbital (RO) at P18, and (iii) intraperitoneal (IP) at P1 (see supplementary materials) shown in Fig. 1C .
After IM injection of P12 mice with AAVs, muscle tissues were analyzed by immunostaining for dystrophin expression 3 weeks later (Fig. 1D  and fig. S6A ). Native GFP identified AAV-mediated gene expression in myofibers. Skeletal muscle from the IM-AAV-injected mice showed a mosaic pattern of dystrophin-positive fibers (Fig. 1D) . The percentage of dystrophin-positive myofibers was calculated as a fraction of total estimated fibers. In the mdx mouse shown in Fig. 1D, 7 .7 ± 3.1% of myofibers in the tibialis anterior (TA) muscle expressed dystrophin 3 weeks after IM-AAV injection (all errors reported are SD). Rescue increased to an estimated 25.5 ± 2.9% of myofibers by 6 weeks after IM-AAV injection (three male mdx mice per group) ( fig. S6A ). Hematoxylin and eosin (H&E) staining of muscle showed that histopathologic hallmarks of muscular dystrophy, such as necrotic myofibers, were diminished in TA muscle at 6 weeks after AAV delivery. Inflammatory cell invasion and centralized myofiber nuclei were minimal, in marked contrast to uninjected control mdx TA (fig. S6B ).
RO injection of AAV into the venous sinus of the mouse represents an alternative to tail vein injection for the systemic administration via blood circulation in young mice. Muscle tissues from mice after RO-AAV injection at P18 were examined by RT-PCR (Fig. 1E) . RT-PCR of RNA from Myoedited mdx mice showed that deletion of exon 23 (DEx23) allowed splicing from exon 22 to 24 (lower band) and the intensity of DEx23 bands was increased from 4 to 12 weeks after RO-AAV injection. Sequencing of RT-PCR products of the DEx23 band confirmed that exon 22 spliced to exon 24 (Fig. 1F) . Muscle tissues were analyzed by immunohistochemistry (Fig. 2) and H&E staining ( fig. S7 ). At 4 weeks after RO-AAV injection in mdx mice, 2.5 ± 1.1% of myofibers were dystrophin-positive, whereas 1.1 ± 0.3% of cardiomyocytes were dystrophin-positive. Progressive improvement with age was also observed from 4 to 8 and 12 weeks after RO-AAV injection. Rescue increased to an estimated 6.1 ± 3.2% of myofibers in TA muscle, and 5.0 ± 2.1% of cardiomyocytes, by 8 weeks after RO-AAV injection. At 12 weeks after injection, 4.6 ± 3.2% of myofibers were dystrophin-positive in TA muscle and 9.6 ± 3.9% of cardiomyocytes were dystrophin-positive. Western blot analysis confirmed the restoration of dystrophin expression in both heart and skeletal muscle ( fig. S8) .
After IP injection of AAV editing components ( fig. S9 ), dystrophin expression was rescued in 1.4 ± 1.2% of TA myofibers and 1.1 ± 1.1% of cardiomyocytes in treated mdx mice after 4 weeks. Higher percent correction was observed in mdxinjected mice at 8 weeks after IP-AAV injection with 1.8 ± 1.2% of dystrophin-positive myofibers and 3.2 ± 2.4% dystrophin-positive cardiomyocytes. Grip strength testing (see supplementary materials) showed a significant increase in strength of mdx mice at 4 weeks after IP-AAV injection relative to uninjected mdx controls (Fig. 3) .
Semiquantitative immunohistochemistry was performed to quantify dystrophin expression levels, normalized to laminin, in wild-type (WT) and AAVinjected mdx mice (see supplementary materials). Integrated density measurements of sarcolemmal staining in TA myofibers showed dystrophin protein levels that were 23.7 ± 11.6% of WT after AAV-IP injection, 27.7 ± 6.6% of WT after AAV-RO injection, and 53.2 ± 18.5% of WT after AAV-IM injection (figs. S10 and S12A). Integrated density of dystrophin in cardiomyocytes showed dystrophin protein levels that were 52.4 ± 14.3% of WT after AAV-IP injection, 71.1 ± 21.0% of WT after AAV-RO injection, and 69.7 ± 19.8% of WT after AAV-IM injection (figs. S11 and S12B).
IM, RO, and IP injection all provide transducing potential in organs and muscle groups remote from the injection site, presumably through intravasculature circulation of AAV. Dystrophin expression in mdx mice was restored in vascular smooth muscle cells by all three modes of AAV delivery, but most effectively by RO ( fig. S13A ). In contrast, no mode of AAV delivery was able to cross the blood-brain barrier to restore dystrophin expression in hippocampal CA1/CA2 regions of mdx mice ( fig. S13, B and C) . AAV transduction across the blood-brain barrier and subsequent restoration , mdx, and AAV-RO-treated mdx mice at 4, 8, and 12 weeks after injection (AAV-RO at P18, four male mdx mice in each group). TA muscle of unedited mdx control mice exhibits myonecrosis, indicated by cytoplasm-filling autofluorescence (highlighted with white asterisks). (B) Dystrophin immunostaining of the heart is illustrated for WT, mdx, and AAV-RO-treated mdx mice at 4, 8, and 12 weeks after injection (AAV-RO at P18, four male mdx mice in each group). Arrowheads indicate dystrophin-positive cardiomyocytes 4 weeks after AAV-RO injection into mdx mouse heart. Scale bar, 40 mm. Fig. 3 . Forelimb grip strength of mdx, mdx-AAV-IP, and wild-type mice 4 weeks after injection. mdx, mdx-AAV-IP, and WT mice were subjected to grip strength testing to measure muscle performance (grams of force), and the mdx-AAV-IP mice showed enhanced muscle performance relative to mdx mice at 4 weeks of age (mdx male control, 34.7 ± 1.8%; mdx-AAV-IP male mice, 48.4 ± 2.5%; WT male, 71.8 ± 1.9%; mdx female control, 29.7 ± 1.4%; mdx-AAV-IP female mice, 45.5 ± 1.4%; WT female, 75 ± 2.4%). Numbers of mice in each group are labeled in the bar, six trials for each mouse. Data are means ± SEM. Significant differences between conditions are indicated (***P < 0.0005). of brain dystrophin expression will likely require other methods (20) (21) (22) (23) . We also harvested sperm from AAV-injected male mdx mice and tested gene editing by T7E1 assay. No cleavage bands were detected (fig. S13D) ; however, more sensitive methods such as deep sequencing might be required to evaluate the risk of unexpected germline editing. Additionally, AAV vectors with tissuespecific promoters should enhance the safety of systemic gene editing.
Our results show that AAV-mediated Myoediting can rescue the reading frame and expression of dystrophin in postnatal mdx mice. The efficiency of restoration of dystrophin-positive myofibers increases with time, likely reflecting persistent expression of gene-editing components. Exon skipping by NHEJ-mediated genomic editing allows for the permanent removal of the disease-causing mutation and was about 10 times as efficient as gene correction by HDR (7) . Myoediting by NHEJ does not require precise genetic modification. Instead, any types of indels that disrupt either a splice donor or acceptor sequence in a mutant exon result in exon skipping. It is noteworthy that the consensus sequence for splice acceptors is NAG, corresponding to the PAM sequence for Cas9 from S. pyogenes (NGG or NAG), so any exon can potentially be skipped by this approach.
It has been estimated that even low-level expression of dystrophin (4 to 15%) can partially ameliorate cardiomyopathy (24) and protect against eccentric contraction-induced injury in skeletal muscle (25) . The efficiency of restoration of dystrophin expression observed after delivery of Myoediting components to mdx mice by AAV is therefore within the range expected to provide therapeutic benefit.
Off-target effects are a safety concern in the eventual translation of gene-editing methods to humans. We did not observe off-target mutations at 10 potential off-target sites in the mouse genome nor any abnormalities in mice after AAV9 delivery of Myoediting components. However, off-target mutations may occur at sites beyond those predicted in silico; hence, a comprehensive and unbiased analysis, such as whole-genome sequencing, would be an essential component of future efforts to establish the safety of this approach (26) (27) (28) . Given that Myoediting offers the potential for durable and progressive therapeutic response in postmitotic adult tissue, we propose that this methodology may warrant investigation as a way to restore muscle function in DMD patients, alone or in combination with other therapies (3, 29) . D uchenne muscular dystrophy (DMD) is among the most prevalent fatal genetic diseases, occurring in 1 out of 5000 male births (1). It results in muscle degeneration, loss of mobility, and premature fatality. DMD mutations are often deletions of one or more exons in the dystrophin gene that disrupt the reading frame of the gene and lead to a complete loss of functional dystrophin expression (2) . In contrast, Becker muscular dystrophy (BMD) is associated with much milder symptoms relative to DMD and is caused by internal, in-frame deletions of the dystrophin gene, resulting in expression of a truncated but partially functional dystrophin protein (3). Because of the genetic nature of the disease, gene therapy is a promising option to treat DMD. However, the very large size of the dystrophin cDNA presents a challenge to gene delivery. Consequently, some therapeutic strategies aim to generate a BMDlike dystrophin. These approaches include the development of mini/micro-dystrophin genes for delivery by adeno-associated virus (AAV) vectors (4-7) and oligonucleotide-mediated exonskipping therapies designed to restore the reading frame of the transcript (8, 9) . For example, removal of exon 51 can address 13% of DMD patient mutations, and exon-skipping strategies could be extended to other regions of the gene to collectively treat 83% of DMD patients (10) . In
